AbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development

Nicholas Donoghoe, Executive vice president, chief business and strategy officer, AbbVie

“At AbbVie, we are focused on applying AI where it can create meaningful impact for our business and, ultimately, for patients.”

Nicholas Donoghoe, Executive vice president, chief business and strategy officer, AbbVie

“As clinical data continues to grow in volume and complexity, partnerships like Valkai help us generate insights faster and enable our teams to spend more time on the decisions that matter most.”

Nicholas Donoghoe, Executive vice president, chief business and strategy officer, AbbVie

“By combining advanced AI capabilities with human expertise, we can help bring new medicines to patients more efficiently.”

Vignesh Rajendran, Co-founder and chief executive officer, Valkai

“We're delighted to partner with AbbVie, combining advanced AI capabilities with deep scientific expertise.”

Vignesh Rajendran, Co-founder and chief executive officer, Valkai

“AbbVie's scale, innovation and unwavering focus on patients make this the kind of partnership that can turn bold ambition into meaningful impact.”

Andrew Campbell, M.D., Vice president, clinical sciences, AbbVie

“For Clinical Sciences in particular, success depends on the ability to learn quickly, adapt intelligently and make confident decisions based on an ever-growing body of evidence.”

Andrew Campbell, M.D., Vice president, clinical sciences, AbbVie

“AI capabilities, like Valkai, have the potential to help us reduce time spent on manual processes and focus more attention on scientific interpretation and clinical strategy, and ultimately, the insights that can advance medicines for patients.”